TUNNELPHARMA Trademark

Trademark Overview


On Wednesday, November 1, 2023, a trademark application was filed for TUNNELPHARMA with the United States Patent and Trademark Office. The USPTO has given the TUNNELPHARMA trademark a serial number of 98250389. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Tuesday, October 15, 2024. This trademark is owned by MinakiLabs. The TUNNELPHARMA trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Software as a service (SAAS) services featuring software for analyzing and reporting self-assessment of illness; Software as a service (SAAS) services featuring software for analyzing and reporting self-assessment of illness for the purpose of ensuring patient safety, tracking infectious disease spread, monitoring mental health conditions, assessing risk of addiction, uncovering pharmaceutical and hospital profiteering practices, and providing therapeutic guidance for mental health improvement. contact tracing; Software as a service (SAAS) services featuring software for identifying persons with possible exposure to drug-related risks, price disparities, pharmaceutical product recalls, malpractices in the healthcare industry, availability of critical medicines, and potential mental health challenges. to facilitate contact tracing; Software as a service (SAAS) services featuring software for monitoring persons with possible exposure to potential drug side effects, risks of addiction, ad...
tunnelpharma

General Information


Serial Number98250389
Word MarkTUNNELPHARMA
Filing DateWednesday, November 1, 2023
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateTuesday, October 15, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Pseudo MarkTUNNEL PHARMA
Goods and ServicesSoftware as a service (SAAS) services featuring software for analyzing and reporting self-assessment of illness; Software as a service (SAAS) services featuring software for analyzing and reporting self-assessment of illness for the purpose of ensuring patient safety, tracking infectious disease spread, monitoring mental health conditions, assessing risk of addiction, uncovering pharmaceutical and hospital profiteering practices, and providing therapeutic guidance for mental health improvement. contact tracing; Software as a service (SAAS) services featuring software for identifying persons with possible exposure to drug-related risks, price disparities, pharmaceutical product recalls, malpractices in the healthcare industry, availability of critical medicines, and potential mental health challenges. to facilitate contact tracing; Software as a service (SAAS) services featuring software for monitoring persons with possible exposure to potential drug side effects, risks of addiction, adverse reactions, the effects of essential medications, tracking their mental well-being, and observing industry malpractices. to facilitate contact tracing; Software as a service (SAAS) services featuring software for notifying persons of possible exposure to potential drug interactions, price changes, price gouging activities, updates on vital medications, hospital profiteering practices, and potential mental health risks or triggers. to facilitate contact tracing; Software as a service (SAAS) services featuring software for recording and analyzing real-time location data for predicting the spread of an illness in a community; Software as a service (SAAS) services featuring software for aiding the uninsured in acquiring prescription benefits, offering access to discounted prices for essential and life-saving drugs, lobbying for the provision of mental health drugs, and providing support to individuals with undiagnosed or unaddressed mental health conditions.; Software as a service (SAAS) services featuring software for real-time tracking of essential drug availability, integrating with pharmacy inventory systems, streamlining the drug acquisition process across various categories, offering support for patients in debt due to hospital bills, assisting in restoring credit scores affected by medical debt, and offering therapeutic AI-driven mental health support.; Software as a service (SAAS) services featuring software using artificial intelligence for analyzing and predicting drug price trends, exposing pricing disparities, uncovering industry corruption, tracking hospital profit margins, providing transparency in drug pricing for consumers, assessing the availability of vital medications for critical conditions, evaluating and scoring individuals for potential mental health issues, and analyzing risks of addiction.; Software as a service (SAAS) services, namely, hosting software for use by others for pharmaceutical analytics, exposing pricing disparities, monitoring drug prices for potential price gouging, highlighting profit margins by hospitals and pharmaceutical companies, offering insights into essential and life-saving medications, and aiding in mental health research.; Research and development of computer software; Research, development, design and upgrading of computer software

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, November 1, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameMinakiLabs
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressJoliet, IL 60435

Trademark Events


Event DateEvent Description
Friday, January 19, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 27, 2024NON-FINAL ACTION WRITTEN
Thursday, June 27, 2024NON-FINAL ACTION E-MAILED
Thursday, June 27, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, November 1, 2023NEW APPLICATION ENTERED
Wednesday, June 12, 2024ASSIGNED TO EXAMINER
Tuesday, October 15, 2024ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, October 15, 2024ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND